Raymond James Maintains Outperform on Abbott Laboratories, Raises Price Target to $129

Benzinga · 10/14 17:11
Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $122 to $129.